Clinical Trials Directory

Trials / Terminated

TerminatedNCT02774681

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Northwestern University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate if the study drug palbociclib has anti-tumor activity against the breast cancer that has spread to the brain and also to determine the overall radiographic response rate in the CNS. Palbociclib is an anti-cancer medication that has been shown to stop cancer cells from growing. It has been approved in hormone positive breast cancer, along with other hormone therapies and has been found to be effective. The preclinical studies suggest that the drug may also have activity in other types of breast cancer, such as HER2 positive breast cancer. The purpose of this study is to see if the study drug is effective in patients with brain metastasis, who have HER2-positive breast cancer.

Detailed description

PRIMARY OBJECTIVES: I. To determine the radiographic response rate in the central nervous system (CNS) in patients with HER2-positive breast cancer who have brain metastasis treated with palbociclib. SECONDARY OBJECTIVES: I. To determine the progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive breast cancer who have brain metastasis treated with palbociclib. II. To determine time to CNS progression in patients with HER2-positive breast cancer who have brain metastasis treated with palbociclib. III. To determine systemic overall response rate (ORR) in patients with HER2-positive breast cancer who have brain metastasis treated with palbociclib. IV. To determine the safety and tolerability of palbociclib in patients with and HER2-positive breast cancer. TERTIARY OBJECTIVES: I. To evaluate circulating tumor deoxyribonucleic acid (DNA) at baseline, 2 month and 4 months; particularly to assess cyclin D1 aberrations, and if this is predictive of responses. II. To evaluate genomic landscape of available CNS and non-CNS tumors, and describe any discordance. III. To evaluate cognitive function and quality of life at baseline, 2 and 4 months in patients receiving palbociclib. OUTLINE: Patients receive palbociclib orally (PO) daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab intravenously (IV) as standard of care concurrently with palbociclib. After completion of study treatment, patients are followed up at 3, 6, 9, and 12 months, and then every 6 months for up to 3 years.

Conditions

Interventions

TypeNameDescription
PROCEDURECognitive AssessmentAncillary studies
DRUGPalbociclibGiven PO
PROCEDUREQuality-of-Life AssessmentAncillary studies
BIOLOGICALTrastuzumabGiven IV

Timeline

Start date
2016-08-31
Primary completion
2019-02-13
Completion
2020-02-16
First posted
2016-05-17
Last updated
2020-04-14
Results posted
2020-02-24

Locations

3 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT02774681. Inclusion in this directory is not an endorsement.